TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00570011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: 3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: 6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
Study: NCT04003207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human Growth hormone
Description: Subcutaneous growth hormone injections given once daily at a dose between 0.15mg/kg/week to 0.47 mg/kg/week titrated based on IGF-1 levels in serum for a duration of 12 weeks.
Study: NCT02285023

Intervention type: OTHER
Intervention: CU-Q2oL
Description: The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.~At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.~At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire.
Study: NCT03268954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine intravenous or subcutaneous formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine intravenous or subcutaneous formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.
Study: NCT04113733

Intervention type: OTHER
Intervention: Sample Collection
Description: Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.

Intervention type: OTHER
Intervention: Sample Collection
Description: Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.
Study: NCT03669757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 134310
Description: Active substance: LEO 134310 is a compound in development at LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 134310
Description: Active substance: LEO 134310 is a compound in development at LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 134310
Description: Active substance: LEO 134310 is a compound in development at LEO Pharma A/S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 134310
Description: Active substance: LEO 134310 is a compound in development at LEO Pharma A/S

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 134310 vehicle
Description: Active substance: none

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% betamethasone valerate ointment (class III steroid)
Description: Active substance: betamethasone valerate
Study: NCT03913013

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-Focused Treatment with MCC App
Description: 12 sessions of family-focused therapy plus use of a mobile app that enhances the skill training taught in the sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment with MCC App
Description: 12 sessions of family-focused therapy plus use of a mobile app that enhances the skill training taught in the sessions.
Study: NCT01108731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study.
Study: NCT01924273

Intervention type: DRUG
Group type: OTHER
Intervention: Talaporfin sodium
Description: Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
Study: NCT02082080

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social support
Study: NCT03608501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.
Study: NCT00157196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide \[L-BLP25\]) at 6-week intervals, commencing at Week 13, until disease progression is documented.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single low dose cyclophosphamide
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best standard of care (BSC)
Description: The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
Study: NCT03848130

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan Knee Taping with Home Exercises
Description: Each patient in group I i.e. taping group with home exercises was given 40 minutes session. Each session started in sitting or lying position with leg extended and mulligan tape was used. Taping was started in the middle of patella, at the level of superior aspect of patella and pulled the tape medially and fixed the tape at medial border. This tilts the lateral border of patella away from femur and produced skin wrinkling. Besides this, home exercises such as quads isometrics and self stretchings \& ROMs were also guided. This session was repeated three times a week for one month (Total 12 sessions/ one month).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lateral wedge insoles with Home Exercises
Description: Each patient in group II i.e. lateral wedge insole with home exercises group was given 20-minute session. In each session, Lateral wedge insoles of 7mm made of silicon or ledos material were advised and home exercises in the same way. This session was repeated once a month but evaluations were obtained after a complete week for one month. (Total 4 sessions/one month)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physiotherapy with Home Exercises
Description: Each patient in group III i.e. traditional physiotherapy with home exercises group was given 40 to 45-minute session. Each session started in lying position. In each session, therapeutic ultrasound with 1.5MHz frequency and continuous mode for 7 minute was given. Then passive stretchings of the following muscle groups was done; calf, hamstring, quadriceps, hip flexors and hip adductors \& abductors and followed by strengthening exercises manually and with quadriceps bench. Home exercises were guided in the same way. This session was repeated 3 to 4 times a month. (Total 12 to 16 sessions/ one month)
Study: NCT02781129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: Stimulation applied will be within parameters commonly used for the treatment of epilepsy during periods of encoding, recall, and memory maintenance .
Study: NCT03944265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Participate in treatment decision counseling session
Study: NCT03608501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide capsules.
Study: NCT03944265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study: NCT03608501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets.
Study: NCT02655939

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reflex Plus
Description: Collagen Hydrolysate: 5g ,Rosehip aqueous extract 0.55g,

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fructose,Orange flavor and sucralose
Study: NCT01446900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/mq, IV on day 1 of each 28 day cycle for 4 cycles. 375 mg/mq IV every 2 months for a total of 8 administrations as additional infusions for patients, who achieve a partial response or complete response after the therapy with R- 2-CdA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 0,1 mg/Kg, SC from day 1 to day 5 of each 28 day cycle for 4 cycles.
Study: NCT01672697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT) and Behavioral Therapy (BT)
Description: 1. Physical Therapy (PT) Protocol states that each participant in the treatment arm only will undergo a total of four 45-minute sessions with a certified pelvic floor (PF) physical therapist over the course of the 12 weeks. Routine monitoring of patient progress will be performed. Each session includes using the body core muscles and internal pelvic floor muscles, focusing on PF protection techniques, PF exercises, Core exercises, progression to full ADLs(activities of daily living), and an exercise routine.~2. Behavioral Therapy (BT) Instructions are given only to participants in the treatment arm after randomization at week-2 visit; handout provides specific instructions about appropriate diet, hygiene and level of activity during the 12 weeks of enrollment.
Study: NCT01916213

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PICSI
Description: If the oocytes are randomized to ICSI during the retrieval they will be ordered by the 1,4,5 8th best oocyte and PICSI to the 2,3, 6 7th best oocytes or the reverse if PICSI is selected. If one cohort is superior that cohort should be chosen by the blinded physician and the alternate cohort frozen or discarded based on their quality. This will ensure that the couple will always have the opportunity to have good quality embryo transferred regardless of how they are randomized. If there are no good quality embryos in the selected cycle we will consider it a failed transfer for that cycle and we will transfer the good quality embryos from the non- selected group as a fresh embryo transfer. For example if a couple is randomized to ICSI and all the ICSI embryos are poor quality but the PICSI embryos are good quality we will consider it a failed ICSI transfer and transfer the PICSI embryos as a fresh embryo transfer.
Study: NCT01360749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lambdalina® (Lidocaine 4% cream)
Description: Lambdaline dose: 2 g for 10 cm2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lambdalina® (Lidocaine 4% cream)
Description: Lambdaline dose: 2 g for 10 cm2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose: 2 g for 10 cm2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose: 2 g for 10 cm2.
Study: NCT03006497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program based on motor learning principles
Description: The exercise program will include simple activities exposing volunteers in various environmental conditions with a view to adjust their head posture in such conditions. The progressiveness of exercises will be based on the two-dimensional classification system of Gentile (1987). Furthermore, external attentional focus will be used.
Study: NCT01513161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nalfurafine hydrochloride (TRK-820)
Description: Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nalfurafine hydrochloride (TRK-820)
Description: Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01876030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Study: NCT00090480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute - Breast cancer vaccine
Description: Cells will be injected intradermally for four weeks for four cycles. Dosage will vary from 10 million to 100 million HAB cells.
Study: NCT04822454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Night shift shadowing program
Description: Our population, made up of 70 students, was divided into two randomly randomized groups: 31 (44.3%) had five night shift shadowing duty prior to their first official night shifts, and 39 (55.7%) did not participate in the shadowing program.
Study: NCT03115203

Intervention type: OTHER
Group type: OTHER
Intervention: Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
Description: Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis

Intervention type: OTHER
Group type: OTHER
Intervention: Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in healthy subjects
Description: Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle in healthy subjects (data obtained from the SIMOVI project being published).
Study: NCT03432754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Attention Training
Description: The mindfulness-based attention training is closely modeled after the traditional mindfulness-based stress reduction (MBSR) protocol, it incorporates formal MBSR practices such as breath exercises, body scans and long sitting meditations. Specifically, MBAT is an abbreviated version of MBSR with a focus on the cognitive components.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Education
Description: The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning and mind wandering in older adults, will comprise of scientific health and lifestyle information. Lectures will be focused on concepts presented in the book The Culprit and the Cure: Why lifestyle is the culprit behind America's poor health and how transforming that lifestyle can be the cure. Meetings will cover how to begin and maintain a more nutritious diet, classifying healthy choices across food groups, completing stretching/toning exercises, and reviewing homework.
Study: NCT02468414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDGN201 TARGTEPO
Description: MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDGN201 TARGTEPO
Description: MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
Study: NCT02916108

Intervention type: OTHER
Intervention: Reading EEG
Description: EEG recording for 5 minutes (not an intervention)

Intervention type: OTHER
Intervention: Reading EEG
Description: EEG recording for 5 minutes (not an intervention)
Study: NCT03517956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877)
Description: Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part.
Study: NCT03761277

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic SynchroMed™ II infusion system
Description: Implanted infusion system consisting of a pump and catheter, as well as external components of a clinician programmer, refill and catheter access port kits, and the Personal Therapy Manager (myPTM™).

Intervention type: DRUG
Group type: OTHER
Intervention: Preservative-free morphine sulfate (PFMS)
Description: The pharmacological agent used in the pump for this study is limited to a preservative-free morphine sulfate (PFMS).
Study: NCT01950650

Intervention type: BEHAVIORAL
Intervention: No treatment given
Description: Survey conducted through computer-assisted telephone interviewing.

Intervention type: BEHAVIORAL
Intervention: survey
Description: Survey conducted via the Internet.
Study: NCT01044862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole (aromatase inhibitor)
Description: A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
Study: NCT04199975

Intervention type: DEVICE
Group type: OTHER
Intervention: Orthoses
Description: Power-Driven or Mechanical Orthoses
Study: NCT03934580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hallucinated meal
Description: a breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated by participants under hypnosis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Real meal
Description: A real breakfast (white bread plus ham and cheese with 250 ml still water) is consumed by participants
Study: NCT01044862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follicle Stimulating Hormone (gonadotropin)
Description: A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Study: NCT02521636

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotic therapy randomization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy randomization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum PCT dosage
Study: NCT02789150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine (Levophed)
Description: Titrate norepinephrine to MAP 65-70
Study: NCT06795841

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: It was applied for upper respiratory tract over tonsils, trachea, and main bronchi (bilaterally parasternal at the level of angle of Lewis)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial release therapy
Description: technique was applied from supine position, with both hands cupping both diaphragmatic domes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional chest physiotherapy
Description: included traditional chest physiotherapy (postural drainage, percussion and shaking), stretching exercise
Study: NCT02789150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine (Levophed)
Description: Titrate norepinephrine to MAP 85 or greater
Study: NCT04051723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The dexamethasone plus ropivacaine
Description: The local infiltration solution containing 0.25mg Dexamethasone and 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
Study: NCT01749657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arizona
Description: Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arizona
Description: Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
Study: NCT03146962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
Study: NCT01749657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arizona
Description: Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arizona
Description: Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
Study: NCT03255967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DSM-H
Description: Multi-modal quality improvement program for improving the quality of care provided to person with dementia (PWD)-informal caregiver dyads through HHC

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects receive care through usual home healthcare assignment process.
Study: NCT00551343

Intervention type: DRUG
Group type: OTHER
Intervention: Exenatide
Description: 10ug Exenatide single s.c. injection

Intervention type: DRUG
Group type: OTHER
Intervention: Exenatide
Description: 10ug Exenatide single s.c. injection
Study: NCT02791516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection once a month (QM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injections once a month